Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Notification, 9005-9007 [E7-3444]
Download as PDF
Federal Register / Vol. 72, No. 39 / Wednesday, February 28, 2007 / Notices
costs associated with compliance for
these entities are negligible.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
William Blumenthal,
General Counsel.
[FR Doc. E7–3397 Filed 2–27–07; 8:45 am]
Food and Drug Administration
BILLING CODE 6750–01–P
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Premarket
Notification
[Docket No. 2006N–0425]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention (CDC)
AGENCY:
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel: Scientific, Technical
and Operational Services for
Epidemiology, Surveillance and
Laboratory Program, Contract
Solicitation Number (CSN) 2006–N–
08556
sroberts on PROD1PC70 with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces a meeting of the
aforementioned Special Emphasis
Panel.
Time And Date: 12 p.m.–3 p.m.,
March 21, 2007 (Closed).
Place: Teleconference.
Status: The meeting will be closed to
the public in accordance with
provisions set forth in section 552b(c)(4)
and (6), Title 5 U.S.C., and the
Determination of the Director,
Management Analysis and Services
Office, CDC, pursuant to Public Law 92–
463.
Matters To Be Discussed: The meeting
will include the review, discussion, and
evaluation of the scientific merit of
research applications in response to
CSN 2006–N–08556, ‘‘Scientific,
Technical and Operational Services for
Epidemiology, Surveillance and
Laboratory Program.’’
Contact Person For More Information:
Christine Morrison, PhD., Designated
Federal Officer, 1600 Clifton Road,
Mailstop D72, Atlanta, GA 30333,
telephone (404) 639–3098.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both CDC
and the Agency for Toxic Substances
and Disease Registry.
Elaine L. Baker,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. E7–3470 Filed 2–27–07; 8:45 am]
BILLING CODE 4163–18–P
VerDate Aug<31>2005
16:08 Feb 27, 2007
Jkt 211001
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by March 30,
2007.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, Jr., Office of the Chief
Information Officer (HFA–250), Food
and Drug Administration, 5600 Fishers
Lane, Rockville, MD 20857, 301–827–
1472.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance:
SUPPLEMENTARY INFORMATION:
Premarket Notification—21 CFR Part
807; Subpart E—(OMB Control Number
0910–0120)—Extension
Section 510(k) of the Federal Food,
Drug, and Cosmetic Act (the act) (21
U.S.C. 360(k)) and the implementing
regulation under part 807 (21 CFR part
807, subpart E) require a person who
intends to market a medical device to
submit a premarket notification
submission to FDA at least 90 days
before proposing to begin the
introduction, or delivery for
introduction into interstate commerce,
for commercial distribution of a device
intended for human use. Based on the
information provided in the
notification, FDA must determine
whether the new device is substantially
equivalent to a legally marketed device,
as defined in § 807.92(a)(3). If the device
is determined to be not substantially
equivalent to a legally marketed device,
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
9005
it must have an approved premarket
approval application (PMA), Product
Development Protocol or be reclassified
into Class I or Class II before being
marketed. The FDA makes the final
decision of whether a device is
equivalent or not equivalent.
The Medical Device User Fee and
Modernization Act of 2002 (MDUFMA)
(Public Law 107–250) added section
510(o) to the act to establish new
regulatory requirements for reprocessed
single-use devices (SUDs). MDUFMA
was signed into law on October 26,
2002.
Section 510(o) of the act requires that
FDA review the types of reprocessed
SUDs subject to premarket notification
requirements and identify which of
these devices require the submission of
validation data to ensure their
substantial equivalence to predicate
devices. Section 510(o) also requires
that FDA review critical and semicritical reprocessed SUDs that are
currently exempt from premarket
notification requirements and determine
which of these devices require the
submission of premarket notifications to
ensure their substantial equivalence to
predicate devices.
FDA has identified the reprocessed
SUDs that require the submission of
validation data to date. The requirement
to submit validation data for certain
reprocessed single-use devices has been
incorporated into the premarket
notification program. As with all other
devices, new premarket notifications for
reprocessed SUDs will be required as
new manufacturers enter the market or
manufacturers with cleared premarket
notifications make significant changes
to their device. The burden estimates in
this document include the burden for
submitting premarket notifications for
reprocessed SUDs with the burden for
all other devices. FDA may amend the
lists of reprocessed SUDs that require
the submission of premarket
notifications with validation data as
necessary.
Section 807.81 states when a
premarket notification is required. A
premarket notification is required to be
submitted by a person who is:
• Introducing a device to the market
for the first time;
• Introducing or reintroducing a
device which is significantly changed or
modified in design, components,
method of manufacturer, or the
intended use that could affect the safety
and effectiveness of the device.
Section 807.87 specifies information
required in a premarket notification
submission.
Section 204 of the Food and Drug
Administration Modernization Act
E:\FR\FM\28FEN1.SGM
28FEN1
9006
Federal Register / Vol. 72, No. 39 / Wednesday, February 28, 2007 / Notices
(FDAMA) amended section 514 of the
act (21 U.S.C. 360d). Amended section
514 allows FDA to recognize consensus
standards developed by international
and national organizations for use in
satisfying portions of device premarket
review submissions including
premarket notifications or other
requirements. FDA has published and
updated the list of recognized standards
regularly since enactment of FDAMA
and has allowed 510(k) submitters to
certify conformance to recognized
standards to meet the requirements of
§ 807.87. Certification of conformance to
a recognized standard may allow a
manufacturer to submit an abbreviated
510(k). FDA is now seeking approval of
a form (Form FDA 3654) that will
standardize certification of conformance
to a recognized standard. FDA believes
that use of this form will simplify the
certification process for 510(k)
submitters and the review process for
FDA.
Form FDA 3514, a summary cover
sheet form, has been created to assist
respondents in categorizing 510(k)
information for submission to FDA. This
form also assists respondents in
categorizing information for other FDA
medical device programs such as PMAs,
investigational device exemptions, and
humanitarian device exemptions The
total burden (1,000 hours) for Form FDA
3514 has been included in this
information collection. Form FDA 3654
is used in the following information
collections: 0910–0078, 0910–0231, and
0910–0332, but the burden is approved
under this information collection (0910–
0120).
Under § 807.87(h), each 510(k)
submitter must include in the 510(k)
either a summary of the information in
the 510(k) (510(k) summary) or a
statement certifying that the submitter
will make available upon request the
information in the 510(k) (510(k)
statement). If the 510(k) submitter
includes a 510(k) statement in the
submission, § 807.93 requires that the
official correspondent of the firm make
available within 30 days of a request all
information included in the submitted
premarket notification on safety and
effectiveness. This information will be
provided to any person within 30 days
of a request if the device described in
the premarket notification submission is
determined to be substantially
equivalent. The information provided
will be a duplicate of the premarket
notification submission including any
safety and effectiveness information, but
excluding all patient identifiers and
trade secret and confidential
information.
In the Federal Register of November
3, 2006 (71 FR 64711), FDA published
a 60-day notice requesting public
comments on the proposed collection of
information. In response to that notice,
no comments were received.
The most likely respondents to this
information collection will primarily be
medical device manufacturers including
reprocessors of single-use devices, and
initial importers of devices.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
21 CFR Section
FDA Form
Number
Number of
Respondents
807 Subpart E
(807.81,
807.87,
807.92, &
807.93)
Annual Frequency
per Response
Total Annual
Responses
Hours per
Response
Total Hours
3,700
1
3,700
80
296,000
807.87
3514
1,956
1
1,956
0.5
978
807.90(a)(3)
3541
400
1
400
0.25
100
807.87(d) and
(f)
3654
150
1
150
1
150
Totals
1 There
297,228
are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 2.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
No. of
Recordkeepers
21 CFR Section
807.93
sroberts on PROD1PC70 with NOTICES
1 There
Annual Frequency
per
Recordkeeping
2,000
10
Total Annual
Records
Hours per
Recordkeeper
20,000
0.5
are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate Aug<31>2005
16:08 Feb 27, 2007
Jkt 211001
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
E:\FR\FM\28FEN1.SGM
28FEN1
Total Hours
10,000
Federal Register / Vol. 72, No. 39 / Wednesday, February 28, 2007 / Notices
FDA has based these estimates on
conversations with industry and trade
association representatives, and from
internal review of the documents listed
in tables 1 and 2 of this document.
Dated: February 22, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–3444 Filed 2–27–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004D–0193]
Guidance for Industry: Eligibility
Determination for Donors of Human
Cells, Tissues, and Cellular and
Tissue-Based Products; Availability
AGENCY:
Food and Drug Administration,
HHS.
sroberts on PROD1PC70 with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a document entitled
‘‘Guidance for Industry: Eligibility
Determination for Donors of Human
Cells, Tissues, and Cellular and TissueBased Products (HCT/Ps),’’ dated
February 2007. The guidance document
assists establishments with making
eligibility determinations for donors of
human cells, tissues, and cellular and
tissue-based products. The guidance
announced in this document finalizes
the draft guidance, ‘‘Guidance for
Industry: Eligibility Determination for
Donors of Human Cells, Tissues, and
Cellular and Tissue-Based Products
(HCT/Ps),’’ dated May 2004. This
guidance also finalizes the draft
guidance, ‘‘Guidance for Industry:
Preventive Measures to Reduce the
Possible Risk of Transmission of
Creutzfeldt-Jakob Disease (CJD) and
Variant Creutzfeldt-Jakob Disease (vCJD)
by Human Cells, Tissues, and Cellular
and Tissue-Based Products (HCT/Ps),’’
dated June 2002 (Docket No. 2002D–
0266).
DATES: Submit written or electronic
comments on agency guidances at any
time.
ADDRESSES: Submit written requests for
single copies of the guidance to the
Office of Communication, Training, and
Manufacturers Assistance (HFM–40),
Center for Biologics Evaluation and
Research (CBER), Food and Drug
Administration, 1401 Rockville Pike,
suite 200N, Rockville, MD 20852–1448.
Send one self-addressed adhesive label
to assist the office in processing your
VerDate Aug<31>2005
16:08 Feb 27, 2007
Jkt 211001
requests. The guidance may also be
obtained by mail by calling CBER at 1–
800–835–4709 or 301–827–1800. See
the SUPPLEMENTARY INFORMATION section
for electronic access to the guidance
document.
Submit written comments on the
guidance to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.fda.gov/dockets/ecomments.
FOR FURTHER INFORMATION CONTACT: Paul
E. Levine, Jr., Center for Biologics
Evaluation and Research (HFM–17),
Food and Drug Administration, 1401
Rockville Pike, suite 200N, Rockville,
MD 20852–1448, 301–827–6210.
SUPPLEMENTARY INFORMATION:
I. Background
FDA is announcing the availability of
a document entitled ‘‘Guidance for
Industry: Eligibility Determination for
Donors of Human Cells, Tissues, and
Cellular and Tissue-Based Products
(HCT/Ps),’’ dated February 2007. The
guidance announced in this document
assists HCT/P establishments with
complying with the requirements under
part 1271 (21 CFR part 1271), subpart C.
These regulations require HCT/P
establishments to perform an eligibility
determination for most cell and tissue
donors, based on donor testing and
screening for relevant communicable
disease agents and diseases. This
guidance applies only to cells and
tissues procured on or after the effective
date of the regulations contained in part
1271, subpart C (effective date May 25,
2005). This guidance does not replace
the guidance on 21 CFR part 1270,
‘‘Guidance for Industry: Screening and
Testing of Donors of Human Tissue
Intended for Transplantation,’’ dated
July 29, 1997, which continues to apply
to certain tissues recovered before May
25, 2005.
In the Federal Register of June 25,
2002 (67 FR 42789), FDA announced the
availability of the draft guidance
entitled ‘‘Guidance for Industry:
Preventive Measures to Reduce the
Possible Risk of Transmission of
Creutzfeldt-Jakob Disease (CJD) and
Variant Creutzfeldt-Jakob Disease (vCJD)
by Human Cells, Tissues, and Cellular
and Tissue-Based Products (HCT/Ps),’’
dated June 2002. The draft guidance
provides information intended to assist
manufacturers of HCT/Ps in minimizing
the risk of transmission of CJD and vCJD
by HCT/P donors that have been
possibly exposed to the agents of CJD
and vCJD.
In the Federal Register of May 25,
2004 (69 FR 29835), FDA announced the
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
9007
availability of the draft guidance
entitled ‘‘Guidance for Industry:
Eligibility Determination for Donors of
Human Cells, Tissues, and Cellular and
Tissue-Based Products (HCT/Ps),’’ dated
Ma 2004. The draft guidance provided
to HCT/P establishments
recommendations for the appropriate
screening and testing of cell and tissue
donors for relevant communicable
disease agents and diseases, and
recommendations for complying with
the regulations for eligibility
determination for donors of HCT/Ps.
FDA issued these two draft guidances
to assist manufacturers in minimizing
the risk of communicable disease
transmission by donors of HCT/Ps. FDA
received numerous comments on the
two draft guidances and those
comments were considered as the
guidance was finalized. Based on these
comments and additional data, FDA has
identified West Nile Virus, Sepsis, and
Vaccinia as relevant communicable
disease agents or diseases (RCDAD). On
the other hand, FDA has not included
severe acute respiratory syndrome
(SARS-CoV) as an RCDAD in this
guidance because there has been no
laboratory-confirmed person-to-person
transmission of SARS-CoV worldwide
since July 2003. In addition, the
guidance recommends nucleic acid
amplification testing (NAT) for human
immunodeficiency virus (HIV) and
hepatitis C virus (HCV) for both living
and cadaveric donors. The guidance
also modifies and/or clarifies the
following:
• Recommendations for risk factors
for vCJD;
• Physical examination of a living
HCT/P donor;
• Exceptions to the requirement for
determining donor eligibility and
appropriate labeling;
• Screening criteria for HIV–1 group
O, viral hepatitis, syphilis, Chlamydia
trachomatis and Neisseria gonorrhea;
• Deferral criteria for receipt of
human-derived clotting factors;
• Procedures for communicable
disease testing laboratories;
• FDA’s approach to identifying new
RCDADs; and
• Use of gestational carriers or
surrogates.
The guidance announced in this
document finalizes the previously
described draft guidances dated June
2002 and May 2004. The guidance is
being issued consistent with FDA’s good
guidance practices regulation (21 CFR
10.115). The guidance represents FDA’s
current thinking on this topic. It does
not create or confer any rights for or on
any person and does not operate to bind
FDA or the public. An alternative
E:\FR\FM\28FEN1.SGM
28FEN1
Agencies
[Federal Register Volume 72, Number 39 (Wednesday, February 28, 2007)]
[Notices]
[Pages 9005-9007]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-3444]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2006N-0425]
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Premarket
Notification
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by March
30, 2007.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-6974.
FOR FURTHER INFORMATION CONTACT: Denver Presley, Jr., Office of the
Chief Information Officer (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-1472.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance:
Premarket Notification--21 CFR Part 807; Subpart E--(OMB Control Number
0910-0120)--Extension
Section 510(k) of the Federal Food, Drug, and Cosmetic Act (the
act) (21 U.S.C. 360(k)) and the implementing regulation under part 807
(21 CFR part 807, subpart E) require a person who intends to market a
medical device to submit a premarket notification submission to FDA at
least 90 days before proposing to begin the introduction, or delivery
for introduction into interstate commerce, for commercial distribution
of a device intended for human use. Based on the information provided
in the notification, FDA must determine whether the new device is
substantially equivalent to a legally marketed device, as defined in
Sec. 807.92(a)(3). If the device is determined to be not substantially
equivalent to a legally marketed device, it must have an approved
premarket approval application (PMA), Product Development Protocol or
be reclassified into Class I or Class II before being marketed. The FDA
makes the final decision of whether a device is equivalent or not
equivalent.
The Medical Device User Fee and Modernization Act of 2002 (MDUFMA)
(Public Law 107-250) added section 510(o) to the act to establish new
regulatory requirements for reprocessed single-use devices (SUDs).
MDUFMA was signed into law on October 26, 2002.
Section 510(o) of the act requires that FDA review the types of
reprocessed SUDs subject to premarket notification requirements and
identify which of these devices require the submission of validation
data to ensure their substantial equivalence to predicate devices.
Section 510(o) also requires that FDA review critical and semi-critical
reprocessed SUDs that are currently exempt from premarket notification
requirements and determine which of these devices require the
submission of premarket notifications to ensure their substantial
equivalence to predicate devices.
FDA has identified the reprocessed SUDs that require the submission
of validation data to date. The requirement to submit validation data
for certain reprocessed single-use devices has been incorporated into
the premarket notification program. As with all other devices, new
premarket notifications for reprocessed SUDs will be required as new
manufacturers enter the market or manufacturers with cleared premarket
notifications make significant changes to their device. The burden
estimates in this document include the burden for submitting premarket
notifications for reprocessed SUDs with the burden for all other
devices. FDA may amend the lists of reprocessed SUDs that require the
submission of premarket notifications with validation data as
necessary.
Section 807.81 states when a premarket notification is required. A
premarket notification is required to be submitted by a person who is:
Introducing a device to the market for the first time;
Introducing or reintroducing a device which is
significantly changed or modified in design, components, method of
manufacturer, or the intended use that could affect the safety and
effectiveness of the device.
Section 807.87 specifies information required in a premarket
notification submission.
Section 204 of the Food and Drug Administration Modernization Act
[[Page 9006]]
(FDAMA) amended section 514 of the act (21 U.S.C. 360d). Amended
section 514 allows FDA to recognize consensus standards developed by
international and national organizations for use in satisfying portions
of device premarket review submissions including premarket
notifications or other requirements. FDA has published and updated the
list of recognized standards regularly since enactment of FDAMA and has
allowed 510(k) submitters to certify conformance to recognized
standards to meet the requirements of Sec. 807.87. Certification of
conformance to a recognized standard may allow a manufacturer to submit
an abbreviated 510(k). FDA is now seeking approval of a form (Form FDA
3654) that will standardize certification of conformance to a
recognized standard. FDA believes that use of this form will simplify
the certification process for 510(k) submitters and the review process
for FDA.
Form FDA 3514, a summary cover sheet form, has been created to
assist respondents in categorizing 510(k) information for submission to
FDA. This form also assists respondents in categorizing information for
other FDA medical device programs such as PMAs, investigational device
exemptions, and humanitarian device exemptions The total burden (1,000
hours) for Form FDA 3514 has been included in this information
collection. Form FDA 3654 is used in the following information
collections: 0910-0078, 0910-0231, and 0910-0332, but the burden is
approved under this information collection (0910-0120).
Under Sec. 807.87(h), each 510(k) submitter must include in the
510(k) either a summary of the information in the 510(k) (510(k)
summary) or a statement certifying that the submitter will make
available upon request the information in the 510(k) (510(k)
statement). If the 510(k) submitter includes a 510(k) statement in the
submission, Sec. 807.93 requires that the official correspondent of
the firm make available within 30 days of a request all information
included in the submitted premarket notification on safety and
effectiveness. This information will be provided to any person within
30 days of a request if the device described in the premarket
notification submission is determined to be substantially equivalent.
The information provided will be a duplicate of the premarket
notification submission including any safety and effectiveness
information, but excluding all patient identifiers and trade secret and
confidential information.
In the Federal Register of November 3, 2006 (71 FR 64711), FDA
published a 60-day notice requesting public comments on the proposed
collection of information. In response to that notice, no comments were
received.
The most likely respondents to this information collection will
primarily be medical device manufacturers including reprocessors of
single-use devices, and initial importers of devices.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Reporting Burden\1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
Number of Annual Frequency Total Annual Hours per
21 CFR Section FDA Form Number Respondents per Response Responses Response Total Hours
--------------------------------------------------------------------------------------------------------------------------------------------------------
807 Subpart E (807.81, 807.87, 807.92, ................. 3,700 1 3,700 80 296,000
& 807.93)
--------------------------------------------------------------------------------------------------------------------------------------------------------
807.87 3514 1,956 1 1,956 0.5 978
--------------------------------------------------------------------------------------------------------------------------------------------------------
807.90(a)(3) 3541 400 1 400 0.25 100
--------------------------------------------------------------------------------------------------------------------------------------------------------
807.87(d) and (f) 3654 150 1 150 1 150
--------------------------------------------------------------------------------------------------------------------------------------------------------
Totals ................. ................. ................. ................. ................. 297,228
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.
Table 2.--Estimated Annual Recordkeeping Burden\1\
----------------------------------------------------------------------------------------------------------------
Annual Frequency
21 CFR Section No. of per Total Annual Hours per Total Hours
Recordkeepers Recordkeeping Records Recordkeeper
----------------------------------------------------------------------------------------------------------------
807.93 2,000 10 20,000 0.5 10,000
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
[[Page 9007]]
FDA has based these estimates on conversations with industry and
trade association representatives, and from internal review of the
documents listed in tables 1 and 2 of this document.
Dated: February 22, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7-3444 Filed 2-27-07; 8:45 am]
BILLING CODE 4160-01-S